期刊文献+

肺切除合并心脏大血管切除重建治疗局部晚期肺癌 被引量:117

Lobectomy or pneumonectomy combined with extended resection of the heart, great vessels in the treatment of locally advanced lung cancer
暂未订购
导出
摘要 目的 总结 3 4 9例肺切除合并心脏大血管切除重建术治疗局部晚期肺癌的临床疗效。方法 1 983年 2月~ 2 0 0 0年 1 2月 ,对 3 4 9例肺癌患者施行肺切除合并心脏大血管切除重建术。肺切除合并肺动脉切除重建术 2 0 5例 ;合并部分左心房切除重建术 75例 ;合并上腔静脉切除重建术 6 5例 ,其中 3例同时合并隆凸切除重建术 ;合并胸主动脉切除重建术 4例。结果 本组手术死亡 2例 ,死亡率为 0 .6 %。发生手术并发症5 3例次 ,发生率为 1 5 .2 %。术后 1、3、5和 1 0年生存率分别为 79.3 6 %、5 9.93 %、3 3 .1 4%和 2 3 .5 6 %。结论 肺切除合并受肺癌侵犯的心脏大血管切除重建术能明显提高患者的生存率 ,改善患者预后。 Objective To summarize the results of extended resection of the heart, great vessels, or both in the treatment of 349 patients with locally advanced lung cancer. Methods From February, 1983 to December, 2000, lobectomy or pneumonectomy combined with extended resection of the heart, great vessels or both were carried out in 349 patients with locally advanced lung cancer. The operations included bronchoplastic procedures and pulmonary artery reconstruction in 205 cases, extended resection of left atrium in 75 cases, superior vena cava resection and reconstruction in 65 cases (3 patients had carina resection and reconstruction simultaneously), and aorta resection and reconstruction in 4 cases respectively. Results There were two operative death. The operative mortality was 0.6% in the series. Fifty three patients had operative complications. The 1,3,5 and 10 year survival rates were 79.36%, 59.93%, 33.14% and 23.56% respectively. Conclusion Extended resection of the heart, great vessels or both can remarkably increase the long term survival and improve the prognosis in patients with locally advanced lung cancer.
出处 《中国肺癌杂志》 CAS 2001年第6期403-406,共4页 Chinese Journal of Lung Cancer
关键词 肺肿瘤 心脏大血管重建术 局部晚期肺癌 肺切除术 Lung neoplasms Cardiovascular plasty Locally advanced lung cancer
  • 相关文献

参考文献6

二级参考文献32

  • 1[1]De Pierre A. Overview of the role for neoadjuvant therapy for early-stage non-small cell lung cancer. Lung Cancer,2000,29(Suppl 2)∶124-125.
  • 2[2]Albain KS, Pass HI. Induction therapy before surgery for non-small cell lung cancer. Lung Cancer,2000,29(Suppl 2)∶168-171.
  • 3[3]De Pierre A, Milleron B, Chevret S, et al. French phase Ⅲ trial of preoperative chemotherapy (PCT) in resectable stage Ⅰ (except T1N0), Ⅱ, Ⅲa non-small cell lung cancer (NSCLC). Lung Cancer,2000,29(Suppl 1)∶91.
  • 4[4]Splinter T, Groen H, Smit E, et al. Randomized multicenter phase Ⅱ study of chemotherapy followed by surgery versus surgery alone in stage Ⅰand Ⅱ non-small cell lung cancer (NSCLC). Lung Cancer,2000,29(Suppl 1)∶90.
  • 5[5]Eberhardt W, Korfee S, Wagner H, et al. "Minimal N2-disease”(operable) stage ⅢA non-small cell lung cancer: Prospectively randomized multicenter German phase-Ⅲ-trial of surgery (S) followed by adjuvant radiotherapy (RTx) versus "Trimodality treatment”-Early results of feasibility and toxicity in this setting. Lung Cancer,2000,29(Suppl 1)∶95-96.
  • 6[6]Mattson K, Ten Valde G, Krofta K, et al. Early results of an international phase Ⅲ study evaluating Taxotere as neo-adjuvant therapy for radically-treatable stage Ⅲ NSCLC. Lung Cancer,2000,29(Suppl 1)∶90.
  • 7[7]O'Rourke N, Armour A. Neo-adjuvant chemotherapy in stage Ⅲ NSCLC in the West of Scotland improves the potential for cure. Lung Cancer,2000,29(Suppl 1)∶107.
  • 8[8]Saito Y, Minami K, Kobayashi M, et al. Ten years' experience of induction therapy for locally advanced NSCLC; a single institution study. Lung Cancer,2000,29(Suppl 1)∶89-90.
  • 9[9]Abolhoda A, Martin J, Ginsberg RJ, et al. Morbidity and mortality for pulmonary resections in lung cancer after induction treatment. Lung Cancer,2000,29(Suppl 1)∶89.
  • 10[10]Leo F, Solli P, Veronesi G, et al. Pulmonary function changes after induction chemotherapy with cisplatinum and gemcitabine in stage Ⅲ non small cell lung cancer. Any additional risk for surgery? Lung Cancer,2000,29(Suppl 1)∶129-130.

共引文献219

同被引文献752

引证文献117

二级引证文献426

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部